Vensana Capital

This week we learned of the tragic loss of a valued member of the #medtech community. Our heavy hearts go out to her family and friends. If you or someone you know is in crisis, help is available by calling the National 988 Suicide & Crisis Lifeline. Just dial 988 on your phone or explore the website below for help or how to help someone in need. https://988lifeline.org

We are excited to work alongside @ Okami Medical and longtime colleagues and co-investors to help bring these important technologies to patients and build another market-leading vascular company. Congratulations to the team!

Welcome aboard!

“Everyone wants [ORs] to be more efficient. Doctors and surgeons want to move their day along. They want to come in on time, leave early if they can get all their patients done, have turnover time and have a very pleasant day at the hospital.” Roberta Schwartz captures the spirit of our work together perfectly. Apella is proud to support our partners Houston Methodist in bringing innovation and artificial intelligence to their #ORs, improving provider and patient experiences. Read the full article in HealthITAnalytics: https://lnkd.in/gY6wnK26

Amy Siegel, CEO & Co-Founder of S2N Health, is moderating an all-star panel of venture capital, large medtech, and start-up leaders at The MedTech Conference this year. Their discussion will focus on today’s challenges in funding medtech innovations and explore actionable strategies to attract strategic investors to early-stage funding rounds. Panelists Lori Chmura, CEO at Nyra Medical, Virginia Giddings, VP Exploration at Edwards Lifesciences, Gwen Watanabe, Managing Director at H.I.G. Capital, and Cynthia Yee, Principal at Vensana Capital will provide valuable insights on topics including: ✅ Understanding the unique obstacles startups face in securing funding ✅ How to effectively engage strategic partners in early-stage funding rounds ✅ Where the early stage medtech funding landscape is headed in the future Join us for a compelling conversation that could shape the next wave of investment in early-stage companies ➡ https://lnkd.in/ehXiGFb4 #VentureCapital #Startups #CorporateInvestment #MedTechCon #mtc24 #medtechinmotion

HSBC Innovation Banking (the former SVB team) just released its mid-year report on state of venture funding for #healthcare, which includes trends and insights into which sectors capital is flowing. Thanks to Jonathan Norris and team! https://lnkd.in/gvmKNRSd Highlights: --Vensana Capital made two investments--leading the Series A for iVEAcare, Inc. alongside Treo Ventures and the Series C for Elucent Medical, Inc. alongside RC Capital--and achieved an exit to Stryker with its acquisition of Artelon. --#Peripheral vascular and #neuromodulation have unsurprisingly continued to attract a lot of capital. This is in part due to the growth opportunity as much as it is the capital intensity. We continue to like this space and are enthusiastic about our #IVUS company, Evident Vascular, Inc. --Crossover and long-only funds still active in later stage commercial opportunities, but at largely down or flat rounds. Beware of highly dilutive large amounts of capital and high valuations that limit your future options --#Cardiovascular leads in pre-commercial funding dollars and where large corporate strategics have been most active in pre-approval M&A over the years.

Some great advice in this interview — featuring Jeffry Weinhuff of Visionary Ventures — relevant to all sub-sectors of #medtech. My favorite line is “investment capital is not tuition.” 😂 But the best advice stems from the insight that good exits via IPO or M&A processes with multiple buyers competing for your company require that most medtech companies must prove their value via strong commercial metrics. And doing that takes a lot of time, expertise and money. Plan, hire and raise capital accordingly. At Vensana Capital, our investment process centers on a deep analysis of every aspect of getting a breakthrough medtech innovation to market, no matter what stage of development a company is at today. We like entrepreneurs who believe their innovation can be highly impactful to patients. We love the ones who want to leave no doubt. https://lnkd.in/eDsUqgn6

Congratulations to Aaron Smith and the team at Artelon on their recently announced acquisition by Stryker. A best-in-class team and technology. We are grateful to all who played a role in the development, launch, and commercialization of this therapy, and are excited about the bright future that will be enabled by this partnership. Our sincere thanks and appreciation to an outstanding team: Aaron Smith, Jeff Byrne, Mark Wiltshire, Todd Goede, Jantzen C., Julie O'Connell, Tiffini Wittwer, Matthew VanHorn, Blake Helm, David Marcum, Vincent Omelio, Michael Pandolfi, Andy McClelland, Brent Matthews, Brian Gilmore, Brad Williford, Phil Mundy III, Schafer Kowalchik, Katrina Michael, Chase Thornburg, Brett Cain, Andrew Raines, James Estabrooks, Justin Sluder Mark Cohen, Gary Burbach,  Carter Meyer

Huge congratulations to Aaron Smith and the outstanding team at Artelon for the announced acquisition by Stryker. Incredible execution with a breakthrough product that will wonderful to see even more broadly available to patients through Stryker's reach. Vensana Capital is proud to have been your partner! https://lnkd.in/ebG3WWPd

Huge congratulations to Aaron Smith and the outstanding team at Artelon for the announced acquisition by Stryker. Incredible execution with a breakthrough product that will wonderful to see even more broadly available to patients through Stryker's reach. Vensana Capital is proud to have been your partner! https://lnkd.in/ebG3WWPd